ES2204848T3 - Compuestos con actividad sobre 5-ht1a utiles para el tratamiento de trastornos de la retina externa. - Google Patents

Compuestos con actividad sobre 5-ht1a utiles para el tratamiento de trastornos de la retina externa.

Info

Publication number
ES2204848T3
ES2204848T3 ES01918208T ES01918208T ES2204848T3 ES 2204848 T3 ES2204848 T3 ES 2204848T3 ES 01918208 T ES01918208 T ES 01918208T ES 01918208 T ES01918208 T ES 01918208T ES 2204848 T3 ES2204848 T3 ES 2204848T3
Authority
ES
Spain
Prior art keywords
retinal
retina
rats
ht1a
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01918208T
Other languages
English (en)
Spanish (es)
Inventor
Robert J. Collier, Jr.
Michael A. Kapin
Mark R. Hellberg
Thomas R. Dean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of ES2204848T3 publication Critical patent/ES2204848T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
ES01918208T 2000-03-17 2001-02-23 Compuestos con actividad sobre 5-ht1a utiles para el tratamiento de trastornos de la retina externa. Expired - Lifetime ES2204848T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
US190279P 2000-03-17

Publications (1)

Publication Number Publication Date
ES2204848T3 true ES2204848T3 (es) 2004-05-01

Family

ID=22700682

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01918208T Expired - Lifetime ES2204848T3 (es) 2000-03-17 2001-02-23 Compuestos con actividad sobre 5-ht1a utiles para el tratamiento de trastornos de la retina externa.

Country Status (19)

Country Link
EP (3) EP1263434A1 (US20080131398A1-20080605-C00009.png)
JP (5) JP2003527423A (US20080131398A1-20080605-C00009.png)
KR (3) KR20030016239A (US20080131398A1-20080605-C00009.png)
CN (2) CN1198605C (US20080131398A1-20080605-C00009.png)
AR (1) AR028258A1 (US20080131398A1-20080605-C00009.png)
AT (1) ATE247507T1 (US20080131398A1-20080605-C00009.png)
AU (5) AU2001238552A1 (US20080131398A1-20080605-C00009.png)
BR (3) BR0109193A (US20080131398A1-20080605-C00009.png)
CA (3) CA2400637A1 (US20080131398A1-20080605-C00009.png)
DE (1) DE60100625T2 (US20080131398A1-20080605-C00009.png)
DK (1) DK1263504T3 (US20080131398A1-20080605-C00009.png)
ES (1) ES2204848T3 (US20080131398A1-20080605-C00009.png)
HK (1) HK1051504A1 (US20080131398A1-20080605-C00009.png)
MX (3) MXPA02009071A (US20080131398A1-20080605-C00009.png)
PL (1) PL203709B1 (US20080131398A1-20080605-C00009.png)
PT (1) PT1263504E (US20080131398A1-20080605-C00009.png)
TW (1) TWI268777B (US20080131398A1-20080605-C00009.png)
WO (3) WO2001070223A1 (US20080131398A1-20080605-C00009.png)
ZA (1) ZA200206350B (US20080131398A1-20080605-C00009.png)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
BR0109193A (pt) * 2000-03-17 2003-05-27 Alcon Inc Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
AU2003300915B2 (en) 2002-12-13 2008-08-28 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
CN100563648C (zh) * 2003-04-25 2009-12-02 田边三菱制药株式会社 包含亚烷基二氧苯衍生物的口服组合物
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US6989445B2 (en) 2003-12-15 2006-01-24 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
WO2006022420A1 (ja) 2004-08-25 2006-03-02 Takeda Pharmaceutical Company Limited 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
EP2896624B1 (en) 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
US20110124736A1 (en) 2009-11-09 2011-05-26 Allergan, Inc. Compositions and methods for stimulating hair growth
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
WO2014127243A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
AU2020228289A1 (en) 2019-02-27 2021-09-09 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
CN113784962A (zh) 2019-02-27 2021-12-10 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
WO2023118544A1 (en) * 2021-12-23 2023-06-29 Cilcare Dev 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下1▼―ブロッカー点眼剤
TW270114B (US20080131398A1-20080605-C00009.png) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
WO1998018458A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
BR0109193A (pt) * 2000-03-17 2003-05-27 Alcon Inc Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma

Also Published As

Publication number Publication date
BR0109230A (pt) 2003-06-03
DE60100625T2 (de) 2004-02-26
ZA200206350B (en) 2003-08-08
DK1263504T3 (da) 2003-12-08
CA2400639A1 (en) 2001-09-27
CA2400639C (en) 2011-08-16
AU2005202600B2 (en) 2008-07-31
BR0109193A (pt) 2003-05-27
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
AU4531001A (en) 2001-10-03
JP2011037901A (ja) 2011-02-24
AU2001239836A1 (en) 2001-10-03
AR028258A1 (es) 2003-04-30
KR20030016239A (ko) 2003-02-26
EP1263434A1 (en) 2002-12-11
EP1263504B1 (en) 2003-08-20
WO2001070223A1 (en) 2001-09-27
JP4789231B2 (ja) 2011-10-12
EP1267878A2 (en) 2003-01-02
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
PL358306A1 (en) 2004-08-09
MXPA02009072A (es) 2003-03-12
PL203709B1 (pl) 2009-11-30
KR20020082885A (ko) 2002-10-31
WO2001070222A2 (en) 2001-09-27
MXPA02009071A (es) 2003-05-23
CN1418100A (zh) 2003-05-14
CA2399985A1 (en) 2001-09-27
JP2003527422A (ja) 2003-09-16
CN1198605C (zh) 2005-04-27
TWI268777B (en) 2006-12-21
JP2011153158A (ja) 2011-08-11
KR20030009390A (ko) 2003-01-29
HK1051504A1 (en) 2003-08-08
WO2001070230A3 (en) 2002-04-25
KR100749191B1 (ko) 2007-08-13
JP2003527427A (ja) 2003-09-16
ATE247507T1 (de) 2003-09-15
EP1263504A2 (en) 2002-12-11
WO2001070222A3 (en) 2002-07-25
CA2400637A1 (en) 2001-09-27
WO2001070230A2 (en) 2001-09-27
MXPA02009073A (es) 2003-03-12
CN1418121A (zh) 2003-05-14
JP2003527423A (ja) 2003-09-16
DE60100625D1 (de) 2003-09-25
PT1263504E (pt) 2003-12-31

Similar Documents

Publication Publication Date Title
ES2204848T3 (es) Compuestos con actividad sobre 5-ht1a utiles para el tratamiento de trastornos de la retina externa.
US7763619B2 (en) Compounds with 5-HT1A activity useful for treating disorders of the outer retina
AU2001245310A1 (en) Compounds with 5-HT1A activity useful for treating disorders of the outer retina
US20080004311A1 (en) Histone deacetylase inhibitors for treating degenerative diseases of the eye
CA2347863C (en) Treatment of disorders of the outer retina
US20070088045A1 (en) Histone deacetylase inhibitors for treating degenerative diseases of the eye
US20030119846A1 (en) Compounds with 5-ht activity useful for controlling visual field loss
US20110160308A1 (en) Use of Monoamine Oxidase Inhibitors to Treat Outer Retina Disorders
MXPA01004175A (en) Treatment of disorders of the outer retina